|Bid||3.68 x 800|
|Ask||3.99 x 4000|
|Day's Range||3.68 - 3.86|
|52 Week Range||3.20 - 6.15|
|Beta (3Y Monthly)||2.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.70|
SUNNYVALE, Calif. , Oct. 11, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2018 on Tuesday, October 30, 2018 after the market close. ...
SUNNYVALE, Calif., Oct. 9, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Klinikum rechts der Isar der Technischen Universität München (TUM) clinical team has treated the first cancer patients in Germany with the innovative Radixact® System. This next-generation helical radiation therapy technology replaced an existing, earlier generation TomoTherapy® System at TUM, reinforcing its value to the hospital as a workhorse radiation therapy device capable of treating a wide range of indications from simple to complex.
SUNNYVALE, Calif., Oct. 4, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the clinical team at Healthcare Global Enterprises (HCG) EKO, Kolkata, has treated the first patient in India using the Radixact® System. HCG EKO is part of Healthcare Global Enterprises Ltd HCG, India's largest provider of cancer care.
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...
SUNNYVALE, Calif., Sept. 25, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that published data from two prospective, multi-center studies using differing protocols provide consistent results and reinforce the use of the CyberKnife® System for the effective management of low- and intermediate-risk prostate cancer. The studies were recently published online in the International Journal of Radiation Oncology*Biology*Physics and in the European Urology Oncology. The CyberKnife System delivers radiation with sub-millimeter precision, enhancing clinicians' ability to treat effectively while preserving healthy tissue.
How far off is Accuray Incorporated (NASDAQ:ARAY) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Scientific ...
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Warning! GuruFocus has detected 1 Warning Sign with ARAY. For the last quarter Accuray Inc reported a revenue of $113.8 million, compared with the revenue of $112.1 million during the same period a year ago.
In August, nine analysts are covering Varian Medical Systems (VAR) stock. Three of them have given the stock a “strong buy” rating, three have given it a “hold,” and three have given it a “sell.” The mean rating for VAR stock is 2.67 with a target price of $122. That implies an upside potential of 9.1% over its closing price of $111.83 on August 20.
SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Thursday reported a loss of $946,000 in its fiscal fourth quarter. On a per-share basis, the Sunnyvale, California-based company said it had a loss of 1 cent. The radiation oncology company posted revenue of $113.8 million in the period.
SUNNYVALE, Calif. , Aug. 16, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2018 . Q4 Fiscal 2018 and Recent ...
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Accuray Incorporated (NASDAQ: ARAY ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 16, 2018 at 4:30 PM Eastern Time. ...
SUNNYVALE, Calif., July 25, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Addenbrooke's Hospital clinical team has treated the first cancer patients in the United Kingdom with the innovative Radixact® System. Addenbrooke's Hospital, part of the Cambridge University Hospitals NHS Foundation Trust, purchased one Radixact System through the NHS England radiotherapy equipment upgrade fund, with a second system funded by the Trust.
In addition, he will serve on the Board's Audit Committee. With Mr. Whitters' appointment, the Accuray Board has been expanded to eight members. Mr. Whitters brings significant public company governance experience in the medical technology and medical device industries to Accuray.
SUNNYVALE, Calif. , July 19, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after ...
Stock Research Monitor: WMGI, ZBH, and ARAY LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on VRAY sign up now at www.wallstequities.com/registration . Pre-market today, WallStEquities.com ...
The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.
Accuray Incorporated (NASDAQ:ARAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS over the last few months, increasingRead More...